Companies Ovid Therapeutics
Ovid Therapeutics (OVID): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Ovid Therapeutics’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $1,655,155FY2024
- $1,022,272FY2025
CEO total pay was $1,022,272 in fiscal 2025, down from $1,655,155 in fiscal 2024.
FY2025: salary $515,000 · bonus $0 · stock awards $24,806 · option awards $118,466
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Jeremy Levin | $644,054 | $0 | $0 | $744,645 | $532,000 | $0 | $14,000 | $1,934,699 |
| Executive Chairman and Former Chief Executive Officer | ||||||||
| Margaret Alexander | 515,000 | 0 | 24,806 | 118,466 | 350,000 | 0 | 14,000 | 1,022,272 |
| President and Chief Executive Officer and Former Chief Operating Officer | ||||||||
| Jeffrey Rona | 506,892 | 0 | 24,806 | 118,466 | 305,000 | 0 | 14,000 | 969,164 |
| Chief Business & Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Jeremy Levin | $1,934,699 | $2,774,102 | — | ↓ −839,403 |
| Margaret Alexander | 1,022,272 | 1,655,155 | — | ↓ −632,883 |
| Jeffrey Rona | 969,164 | 1,518,796 | 1,083,970 | ↓ −549,632 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive officer compensation structure is designed to align executive performance with long-term value creation for stockholders. It is our executive compensation strategy to align executive officer performance with strategic corporate goals and the achievement of corporate milestones. We consider the majority of executive compensation to be 'at risk' meaning such compensation is based upon performance and stock price rather than in the form of guaranteed compensation.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards, LLP |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Margaret Alexander | Option | 834 | 3.22 | — |
| Margaret Alexander | Option | 2,084 | 2.72 | — |
| Margaret Alexander | RSU | 18,750 | — | 30,562 |
| Margaret Alexander | RSU | 43,750 | — | 71,312 |
| Margaret Alexander | Option | 47,396 | 2.5 | — |
| Margaret Alexander | Option | 91,407 | 3.68 | — |
| Margaret Alexander | Option | 91,875 | 1.05 | — |
| Margaret Alexander | Option | 96,250 | 1.07 | — |
| Margaret Alexander | Option | 262,500 | 0.57 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Bart FriedmanIndependent · Lead Independent Director · Audit Committee · Compensation Committee · Nominating and Corporate Governance Committee (Chair) | $85,814 | — | $19,940 | — | — | $105,754 |
| Karen BernsteinIndependent · Audit Committee · Compensation Committee (Chair) · Nominating and Corporate Governance Committee · Not standing for re-election | 70,000 | — | 19,940 | — | — | 89,940 |
| Stelios PapadopoulosIndependent · Audit Committee · Compensation Committee | 54,355 | — | 34,551 | — | — | 88,906 |
| Barbara DuncanIndependent · Audit Committee (Chair) · Nominating and Corporate Governance Committee | 66,326 | — | 19,940 | — | — | 86,266 |
| Kevin FitzgeraldIndependent · Nominating and Corporate Governance Committee | 50,000 | — | 19,940 | — | — | 69,940 |
| Jeremy M. LevinEmployee director · Board Chair | — | — | — | — | — | 0 |
| Margaret AlexanderEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 12,500 / 12,500 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $326,495 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $326,495 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Ovid Therapeutics as a peer
Companies that benchmark against OVID
3 companies name OVID as a compensation peer
- Adverum Biotechnologies, Inc.ADVMFY2024
- Alector, Inc.ALECFY2025
- DiaMedica Therapeutics Inc.DMACFY2025
Each company listed discloses OVID in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named OVID in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Ovid Therapeutics | 2025 | Margaret Alexander | $515,000 | $24,806 | $118,466 | $350,000 | $1,022,272 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-10 | 84,511,953 | 8,901,691 | 2,334,071 | 90.47% | Passed |
| 2024 | 2024-06-06 | 40,499,565 | 1,760,461 | 8,185 | 95.82% | Passed |
| 2023 | 2023-06-08 | 44,681,350 | 113,666 | 40,903 | 99.66% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-10 | 90.47%a |
| 2024 | 2024-06-06 | 95.82%b |
| 2023 | 2023-06-08 | 99.66%c |
a. Voting standard not stated in the filing.
b. Approved under the standard stated in the filing — “Abstentions will have the same effect as a vote "Against" this proposal.”.
c. Approved under the standard stated in the filing — “Abstentions will have the same effect as a vote "Against" this proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (16 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Jeremy Levin. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 1,934,699. View filing ↗
- Section 01, Margaret Alexander. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 1,022,272. View filing ↗
- Section 01, Jeffrey Rona. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 969,164. View filing ↗
- Section 08, Bart Friedman. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 105,754. View filing ↗
- Section 08, Karen Bernstein. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 89,940. View filing ↗
- Section 08, Stelios Papadopoulos. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 88,906. View filing ↗
- Section 08, Barbara Duncan. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 86,266. View filing ↗
- Section 08, Kevin Fitzgerald. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 69,940. View filing ↗
- Section 08, Jeremy M. Levin. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Margaret Alexander. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-11. Item 5.07 · say-on-pay result. As reported: 90.47% (votes for as printed: 84,511,953). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-07. Item 5.07 · say-on-pay result. As reported: 95.82% (votes for as printed: 40,499,565). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-09. Item 5.07 · say-on-pay result. As reported: 99.66% (votes for as printed: 44,681,350). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 326,495 + equity 0 + all other 0 = 326,495, summed across the director compensation table rows.
- Ovid Therapeutics (subject), Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Ovid Therapeutics's own proxy. As printed: 1,022,272. View filing ↗